Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Lymphoma

First Posted Date: 2005-09-16

Last Posted Date: 2009-12-29

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 5

Registration Number: NCT00182650

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

Stem Cell Transplant for Immunologic or Histiocytic Disorders

Phase 2

Completed

Conditions: Hemophagocytic Lymphohistiocytosis
X-Linked Lymphoproliferative Disorders
Immunologic Deficiency Syndromes
Chediak-Higashi Syndrome
Griscelli Syndrome
Langerhans-Cell Histiocytosis

Interventions: Procedure: Stem Cell Transplant
Drug: Fludarabine
Drug: Melphalan
Drug: Anti-thymocyte globulin (ATG)
Drug: Campath 1H
Drug: Cyclosporin A
Drug: Mycophenolate mofetil
Drug: Intravenous immunoglobulin (IVIG)

First Posted Date: 2005-09-15

Last Posted Date: 2017-12-28

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 19

Registration Number: NCT00176865

Locations: 🇺🇸
Masonic Cancer Center University of Minnesota, Minneapolis, Minnesota, United States

Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Follicular Lymphoma

Interventions: Drug: rituximab
Drug: fludarabine
Drug: mitoxantrone

First Posted Date: 2005-09-15

Last Posted Date: 2019-08-28

Lead Sponsor: Lymphoma Study Association

Target Recruit Count: 50

Registration Number: NCT00169208

Locations: 🇫🇷
Service d'Hématologie Hôpital St Louis, Paris, France
🇫🇷
Service de médecine D - Maladies du Sang CHU Angers, Angers, France
🇫🇷
Service d'hématologie Institut Paoli Calmette, Marseille, France

and more 13 locations

Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies

Phase 2

Completed

Conditions: Hemoglobinopathies
Sickle Cell Disease
Thalassemia

First Posted Date: 2005-09-12

Last Posted Date: 2013-07-30

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 2

Registration Number: NCT00153985

Locations: 🇺🇸
Winship Cancer Institute-Emory University, Atlanta, Georgia, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 3 locations

Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2

Completed

Conditions: Lymphocytic Leukemia, Chronic
Lymphoma, Small Lymphocytic

First Posted Date: 2005-09-02

Last Posted Date: 2017-02-08

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 8

Registration Number: NCT00143065

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States

Randomized Study for Patients With Follicular Lymphoma Needing Treatment

Phase 3

Completed

Conditions: Follicular Lymphoma

First Posted Date: 2005-09-01

Last Posted Date: 2005-09-01

Lead Sponsor: Lymphoma Study Association

Target Recruit Count: 400

Registration Number: NCT00140569

Locations: 🇧🇪
Groupe d'atude des lymphome de l'adulte, Yvoir, Belgium
🇫🇷
Hôpital Henri Mondor, Créteil, France
🇫🇷
Centre Léon Bérard, Lyon, France

and more 5 locations

Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma

Phase 2

Terminated

Conditions: Melanoma (Skin)

First Posted Date: 2005-08-30

Last Posted Date: 2012-03-29

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 6

Registration Number: NCT00138229

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸
NCI - Surgery Branch, Bethesda, Maryland, United States

Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

Phase 2

Completed

Conditions: Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes

Interventions: Drug: cyclophosphamide
Drug: fludarabine phosphate
Drug: mycophenolate mofetil
Drug: tacrolimus
Procedure: allogeneic bone marrow transplantation
Radiation: radiation therapy

First Posted Date: 2005-08-24

Last Posted Date: 2015-10-06

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 210

Registration Number: NCT00134004

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia, United States
🇺🇸
Hahnemann University Hospital, Philadelphia, Pennsylvania, United States

Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus

Phase 2

Completed

Conditions: Multiple Myeloma
Myelogenous Leukemia
Non-Hodgkin's Lymphoma
Hodgkin's Disease
Lymphoblastic Leukemia

First Posted Date: 2005-08-23

Last Posted Date: 2016-07-25

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 32

Registration Number: NCT00133367

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma

Phase 2

Terminated

Conditions: Lymphoma

Interventions: Drug: fludarabine phosphate
Drug: melphalan
Drug: methotrexate
Drug: tacrolimus
Procedure: allogeneic bone marrow transplantation
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2005-07-21

Last Posted Date: 2012-04-03

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 1

Registration Number: NCT00121186

Locations: 🇺🇸
Cancer Center of Kansas, PA - Dodge City, Dodge City, Kansas, United States
🇺🇸
Cancer Center of Kansas, PA - Medical Arts Tower, Wichita, Kansas, United States
🇺🇸
Cancer Center of Kansas, PA - Pratt, Pratt, Kansas, United States

and more 30 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy